

POLICY Document for Lemtrada

The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific to use of preferred medication options, and overall clinically appropriate use. This document provides specific information to both sections of the overall policy.

Section 1: Preferred Product

- Policy information specific to preferred medications

Section 2: Clinical Criteria

- Policy information specific to the clinical appropriateness for the medication

Section 1: Preferred Product

EXCEPTIONS CRITERIA

MULTIPLE SCLEROSIS

PREFERRED PRODUCTS: TYSABRI and OCREVUS

POLICY

This policy informs prescribers of preferred products and provides an exception process for non-preferred products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the multiple sclerosis products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with the targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Multiple sclerosis (MS) products

	Product(s)
Preferred	<ul style="list-style-type: none">• Ocrevus (ocrelizumab)• Tysabri (natalizumab)
Targeted	<ul style="list-style-type: none">• Lemtrada (alemtuzumab)

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred product.

Coverage for the targeted product is provided when any of the following criteria is met:

1. Member is currently receiving treatment with the targeted product, excluding when the targeted product is obtained as samples or via manufacturer's patient assistance programs.

Specialty Exceptions Multiple Sclerosis MMB P2019
Lemtrada 1843-A SGM P2019

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

2. Member has experienced documented inadequate response(s) and/or intolerable adverse event(s) to treatment with BOTH of the preferred products.
3. Member has documented contraindications to therapy with BOTH of the preferred products (including any of their components).

Section 2: Clinical Criteria

LEMTRADA (alemtuzumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Lemtrada is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

All other indications are considered experimental/investigational and are not covered benefits.

II. CRITERIA FOR APPROVAL

III.

A. First Course – Relapsing forms of multiple sclerosis

Authorization of 30 days (5 doses) may be granted to members with a diagnosis of a relapsing form of multiple sclerosis who have had an inadequate response to two or more drugs indicated for multiple sclerosis.

B. Subsequent Courses – Relapsing forms of multiple sclerosis

Authorization of 30 days (3 doses) may be granted to members with a diagnosis of a relapsing form of multiple sclerosis who have completed at least one previous course of therapy.

IV. OTHER CRITERIA

Members will not use Lemtrada concomitantly with other medications used for the treatment of multiple sclerosis, excluding Ampyra.

For subsequent courses, members must have received the previous course of Lemtrada treatment at least 12 months prior to the planned date of the first dose of Lemtrada course of treatment.

REFERENCES

SECTION 1

1. Lemtrada [package insert]. Cambridge, MA: Genzyme Corporation; December 2017.
2. Ocrevus [package insert]. South San Francisco, CA: Genentech, Inc.; March 2017.
3. Tysabri [package insert]. Cambridge, MA: Biogen Inc; April 2018.

SECTION 2

1. Lemtrada [package insert]. Cambridge, MA: Genzyme Corporation; July 2019.